CROSSJECT news, videos and press releases
For more news please use our advanced search feature.
CROSSJECT - More news...
CROSSJECT - More news...
- Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System
- Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization
- Crossject to report first-half 2024 financial results and host webcast on September 23, 2024
- Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
- Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
- Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
- Crossject announces highly successful closing of its €8 million rights offering
- Crossject trading on Euronext to resume as usual on Wednesday April 3
- Crossject advances in its U.S. Strategy and reports Financial Results for 2023
- Crossject gender equality score reaches 96/100 in 2024
- Crossject obtains a financing up to €12 million, in two tranches
- Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
- Crossject to present at Biotech Showcase on January 9 at 16:30 PT
- Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
- Crossject signs ZEPIZURE® commercialization agreement for northern Europe
- Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures
- Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
- Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
- Crossject - Appointment of Daniel Teper to the Crossject Supervisory Board / Building skills to support the US transition
- CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
- CROSSJECT: Agreement with BARDA on ZENEO® Midazolam
- Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
- Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
- Crossject : Information relative au nombre de droits de vote et d'actions composant le capital social
- CROSSJECT : Financial calendar 2018
